Seth Klarman's firm Baupost Group recently filed an amended 13G with the SEC regarding its position in Idenix Pharmaceuticals (IDIX). Per the filing, Baupost Group now owns 18.48% of the company with 24,740,200 shares.
This marks around a 106% increase in the number of shares they own since the end of the third quarter. The filing was made due to portfolio activity on January 31st.
Per Google Finance, Idenix Pharmaceuticals "is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The Company’s research and development focus is on the treatment of hepatitis C virus (HCV)."
You can see more of Baupost Group's portfolio activity here.
Monday, February 11, 2013
Seth Klarman's Baupost Group Increases Idenix Pharmaceuticals Position
blog comments powered by Disqus
